molecules-logo

Journal Browser

Journal Browser

New Therapeutic Targets for Cancer

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 1472

Special Issue Editor


E-Mail Website
Guest Editor
College of Pharmaceutical Sciences, Zhejiang University, No. 866 Yuhangtang Road, Hangzhou 310058, China
Interests: tumor immunotherapy; vaccine design; nano-medicine; targeted cancer therapy

Special Issue Information

Dear Colleagues,

As a result of the most recent societal and technological developments, the concept of cancer treatment is undergoing a fundamental change from empirical science to evidence-based medicine, and from cellular attack mode to targeted treatment mode. Drug targeted therapy, which applies targeted technology to precisely deliver drugs to the tumor area, and targeted therapy, which uses tumor-specific signaling or specific metabolic pathways, are some of the most popular themes in cancer research.

In this Special Issue, we are pleased to invite our colleagues to present their findings in the field of new therapeutic targets for cancer. In particular, articles reporting mechanisms of new molecular targets and novel targeting technologies are encouraged. This Special Issue aims to provide the most updated insights into targeted cancer therapy, and original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the development of novel targeting approaches, new molecular targets, nano-targeting strategy, targeted regulation of tumor microenvironment, mechanism of anti-tumor drug targeting, anti-tumor chemotherapy drug targeting, and tumor immunotherapy targeting.

Prof. Dr. Lihua Luo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • targeted therapy
  • drug targeted delivery
  • molecular targets
  • nanotechnology
  • pharmaceuticals
  • pharmacology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2481 KiB  
Article
Lipophilic Fe(III)-Complex with Potent Broad-Spectrum Anticancer Activity and Ability to Overcome Pt Resistance in A2780cis Cancer Cells
by Nalin Abeydeera, Morgan Stilgenbauer, Bishnu D. Pant, Khalil Mudarmah, Thiloka M. Dassanayake, Yao-Rong Zheng and Songping D. Huang
Molecules 2023, 28(13), 4917; https://doi.org/10.3390/molecules28134917 - 22 Jun 2023
Cited by 1 | Viewed by 1292
Abstract
Although iron is essential for all forms of life, it is also potentially toxic to cells as the increased and unregulated iron uptake can catalyze the Fenton reaction to produce reactive oxygen species (ROS), leading to lipid peroxidation of membranes, oxidation of proteins, [...] Read more.
Although iron is essential for all forms of life, it is also potentially toxic to cells as the increased and unregulated iron uptake can catalyze the Fenton reaction to produce reactive oxygen species (ROS), leading to lipid peroxidation of membranes, oxidation of proteins, cleavage of DNA and even activation of apoptotic cell death pathways. We demonstrate that Fe(hinok)3 (hinok = 2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one), a neutral Fe(III) complex with high lipophilicity is capable of bypassing the regulation of iron trafficking to disrupt cellular iron homeostasis; thus, harnessing remarkable anticancer activity against a panel of five different cell lines, including Pt-sensitive ovarian cancer cells (A2780; IC50 = 2.05 ± 0.90 μM or 1.20 μg/mL), Pt-resistant ovarian cancer cells (A2780cis; IC50 = 0.92 ± 0.73 μM or 0.50 μg/mL), ovarian cancer cells (SKOV-3; IC50 = 1.23 ± 0.01 μM or 0.67 μg/mL), breast cancer cells (MDA-MB-231; IC50 = 3.83 ± 0.12 μM or 2.0 μg/mL) and lung cancer cells (A549; IC50 = 1.50 ± 0.32 μM or 0.82 μg/mL). Of great significance is that Fe(hinok)3 exhibits unusual selectivity toward the normal HEK293 cells and the ability to overcome the Pt resistance in the Pt-resistant mutant ovarian cancer cells of A2780cis. Full article
(This article belongs to the Special Issue New Therapeutic Targets for Cancer)
Show Figures

Figure 1

Back to TopTop